Supporting Better Lives for CKD Patients
We exist to improve the lives of those with Chronic Kidney Disease and lower the cost of CKD to the worldwide healthcare system.
Our Expertise
Over the past 20 years, the PrognostX Health team has invested $11M in research to discover a novel CKD biomarker for single-assessment detection. Supported by programs from Larta Institute, Eva Garland Consulting, LaunchBlue, and Beckman Coulter Foundation, we've advanced from basic research to groundbreaking innovation.
Patented Biomarker
Unique biomarker discovered after 20 years of research, pivotal in CKD diagnosis.
Single Test Diagnosis
Highly accurate results from just one test, improving patient compliance and diagnosis rates.
Strong Partnership
Collaboration with Ethos Biosciences for strategic manufacturing and commercial rollout.
FDA Pathway Advantage
Pursuing an In Vitro Diagnostics (IVD) pathway, ensuring FDA approval and broad usability across various labs.
The World's Newest Biomarker for CKD
This non-filtration dependent biomarker test offers physicians a new and complementary perspective to renal health. In a 384 patient study, our novel biomarker identified CKD Stages 3a, 3b, and 4 at a 97% accuracy, with an ROC analysis demonstrating 98% sensitivity, 97% specificity, 94% PPV, and 99% NPV (AUC = 0.982) on a single assessment.
Why Us?
PrognostX Health, a clinical diagnostic startup, is revolutionizing Chronic Kidney Disease (CKD) detection with a 97% accurate test on a single assessment.
.svg)
.svg)
Impact on Healthcare
PrognostX Health's test could significantly reduce healthcare costs. By providing early and accurate detection, we aim to improve patient outcomes, reduce the burden on healthcare systems, and ensure timely and effective treatment for CKD.
.webp)
.webp)
.webp)
Latest News
Get One Step Ahead of Disease
.webp)
